NextCure, Inc. Share Price & Technical Analysis
NXTC · $7.83 (-22.55%)
Healthcare / Biotechnology
$7.83
-22.55%
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukem…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
-16% return in May, 18% avg return in past 3 year May month.
-55% return in 2026, 32% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -24% | 19% | -15% | -19% | -16% | – | – | – | – | – | – | – | -55% |
| 25 | 4% | -3% | -38% | 0% | 11% | -11% | -9% | 4% | 20% | 114% | 18% | 1% | 111% |
| 24 | 5% | 42% | 28% | -46% | 28% | 1% | 1% | -8% | -8% | -2% | -11% | -34% | -5% |
| 23 | 18% | -6% | -5% | 2% | 14% | 6% | -4% | -17% | -11% | -19% | 18% | -4% | -9% |
| 22 | -8% | -13% | -3% | -16% | -8% | 19% | -8% | -5% | -32% | -9% | -45% | 2% | -127% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$35.03M
P/E ratio
—
52W high
$15.74
52W low
$4.60
Volume
94,161
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is NextCure, Inc. share price today?
- NextCure, Inc. (NXTC) last traded around $7.83 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does NXTC have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for NXTC. Download the app for real-time alerts.
- How can I analyze NextCure, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.